ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,537.02
0.51%
US Tech 100
19,641.60
0.83%
Dow Jones
39,308.00
-0.06%
Brent Oil
86.705
-0.24%
Bitcoin
57,452.27
-4.50%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. BeiGene Ltd (BGNE)

  7. BeiGene Ltd (BGNE) News

BGNE

BeiGene (BGNE)

BeiGene Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:BGNE
DateTimeSourceHeadlineSymbolCompany
10/12/20227:00AMBusiness WireBeiGene Announces Positive Topline Results from Final Progression-Free Survival Analysis of BRUKINSA® (zanubrutinib) Compared to IMBRUVICA® (ibrutinib) in Phase 3 Chronic Lymphocytic Leukemia (CLL) TrialNASDAQ:BGNEBeiGene Ltd
09/22/20225:35PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:BGNEBeiGene Ltd
09/22/20224:14PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:BGNEBeiGene Ltd
09/19/20227:01PMBusiness WireNICE Recommends BeiGene’s BRUKINSA® (zanubrutinib) for Patients with Waldenström’s Macroglobulinemia who have had at Least One TreatmentNASDAQ:BGNEBeiGene Ltd
09/19/20228:30AMDow Jones NewsBeiGene's Brukinsa Drug Recommended for EU AuthorizationNASDAQ:BGNEBeiGene Ltd
09/19/20227:00AMBusiness WireBeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Marginal Zone LymphomaNASDAQ:BGNEBeiGene Ltd
09/15/20224:38PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:BGNEBeiGene Ltd
09/10/20222:30AMBusiness WireBeiGene Announces Data Presentations at ESMO 2022 Including Late-Breaking Oral Presentation for Tislelizumab in First-Line Unresectable Hepatocellular CancerNASDAQ:BGNEBeiGene Ltd
09/07/20227:27PMBusiness WireBeiGene to Present at the Morgan Stanley 20th Annual Global Healthcare ConferenceNASDAQ:BGNEBeiGene Ltd
08/30/20224:10PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:BGNEBeiGene Ltd
08/23/20227:00AMBusiness WireBeiGene Announces Acceptance of 11th Regulatory Submission for PD-1 Inhibitor Tislelizumab in ChinaNASDAQ:BGNEBeiGene Ltd
08/16/20224:16PMEdgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:BGNEBeiGene Ltd
08/15/20227:00AMBusiness WireBeiGene Announces Strategic Alliance with Ontada to Improve U.S. Community Oncology CareNASDAQ:BGNEBeiGene Ltd
08/09/20227:01PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:BGNEBeiGene Ltd
08/09/20226:00AMBusiness WireBeiGene Announces Positive Global Phase 3 Trial Results for PD-1 Inhibitor Tislelizumab in First-Line Unresectable Hepatocellular CancerNASDAQ:BGNEBeiGene Ltd
08/08/20224:13PMEdgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:BGNEBeiGene Ltd
08/08/20227:15AMEdgar (US Regulatory)Quarterly Report (10-q)NASDAQ:BGNEBeiGene Ltd
08/04/20227:08AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:BGNEBeiGene Ltd
08/04/20227:00AMBusiness WireBeiGene Reports Second Quarter 2022 Financial ResultsNASDAQ:BGNEBeiGene Ltd
07/20/20225:08PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:BGNEBeiGene Ltd
07/18/20225:23PMEdgar (US Regulatory)Amended Statement of Changes in Beneficial Ownership (4/a)NASDAQ:BGNEBeiGene Ltd
07/17/202211:17PMTipRanksBeiGene (BGNE) Receives a Hold from SVB SecuritiesNASDAQ:BGNEBeiGene Ltd
07/15/20224:13PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:BGNEBeiGene Ltd
07/15/202212:47PMTipRanksBeiGene (BGNE) Gets a Buy Rating from Morgan StanleyNASDAQ:BGNEBeiGene Ltd
07/14/20226:48AMDow Jones NewsBeigene Says FDA Defers Action on BLA Due to Covid Travel RestrictionsNASDAQ:BGNEBeiGene Ltd
07/14/20226:00AMBusiness WireBeiGene Provides Regulatory Update on the U.S. Biologics License Application (BLA) for PD-1 Inhibitor Tislelizumab in 2L ESCCNASDAQ:BGNEBeiGene Ltd
07/13/20229:00AMBusiness WireBeiGene Appoints Chan Lee as General CounselNASDAQ:BGNEBeiGene Ltd
07/12/20227:00AMPR Newswire (US)Leap Therapeutics Announces Initiation of New DKN-01 Clinical Trials in Gastric Cancer, Colorectal Cancer and Endometrial CancerNASDAQ:BGNEBeiGene Ltd
07/07/202210:48PMTipRanksBeiGene (BGNE) Receives a Hold from SVB SecuritiesNASDAQ:BGNEBeiGene Ltd
07/06/20227:00AMBusiness WireBeiGene Announces Strategic Research Collaboration with InnoRNA to Jointly Discover Novel mRNA TherapiesNASDAQ:BGNEBeiGene Ltd
 Showing the most relevant articles for your search:NASDAQ:BGNE

Your Recent History

BIT
P201N2
NLBNPIT201N2 20991231 21...
BIT
UC4VD7
Unicredit Bank
BIT
P1U9S0
BNP Paribas Issuance
NASDAQ
VIIAW
7GC
BIT
UC24CM
Unicredit Bank
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved